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Abstract
We extend multi-way, multivariate ANOVA-type analysis to cases where one
covariate is the view, with features of each view coming from different, high-
dimensional domains. The different views are assumed to be connected by having
paired samples; this is a common setup in recent bioinformatics experiments, of
which we analyze metabolite profiles in different conditions (disease vs. control
and treatment vs. untreated) in different tissues (views). We introduce a multi-
way latent variable model for this new task, by extending the generative model of
Bayesian canonical correlation analysis (CCA) both to take multi-way covariate
information into account as population priors, and by reducing the dimensionality
by an integrated factor analysis that assumes the metabolites to come in correlated
groups.
1 Introduction
Finding disease and treatment effects from populations of measurements is a prototypical multi-way
modeling task, traditionally solved with multivariate ANOVA. Here disease state (diseased/healthy)
and treatment (treated/placebo) are the two covariates, and the research question is, are there dif-
ferences in the population that can be explained by either covariate or, more interestingly, their
interaction, which would hint at the treatment being effective. It is naturally additionally interesting
what the differences are.
A recurring problem in multi-way analyses, especially with modern high-throughput measurements
in molecular biology, is the ”small n, large p”-problem. The dimensionality p of the measurements is
high while the number of samples n is low, and additionally the data may be collinear making estima-
tion of the effects impossible with classical methods, univariate or multivariate linear models solved
with multi-way ANOVA techniques. The most promising modern method, Bayesian sparse factor
regression model [1], is useful in finding the variables most strongly related to the external covariate
and to infer relationships between those variables via common latent factors. Instead of a regression
model we will use a generative latent factor model which incorporates an assumption of clustered-
ness of the variables to regularize the model, and makes it possible to extend the model to multi-view
factor analysis. Such clusteredness is well justified in our application field, metabolomics, where
due to biochemical reaction pathways the variation in concentrations of metabolite groups is highly
correlated [2].
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Assume that measurements have been made on the same objects but with different methods, resulting
in different data sources possibly on different domains. An example we will analyze in this paper is
metabolomic profiles in different tissues, where the domains are partly different since the metabolites
cannot be fully matched. The different views form one covariate in the multi-way analysis, with the
additional problem that the samples come from different domains and cannot be directly compared.
We introduce a new hierarchy level of latent variables intended to decompose the views into view-
specific and shared components, which is needed for the multi-way analysis. Such a decomposition
is possible given that the samples in the different views come in pairs, which we need to assume.
The resulting decomposition between the views turns out to be implementable with Bayesian canon-
ical correlation analysis [3, 4, 5], interpretable as unsupervised multi-view modeling. Hence, in this
work we re-interpret unsupervised multi-view modeling as one-way modeling of samples from dif-
ferent domains, and combine it with multi-way modeling. Given that we additionally can work
under the large p, small n conditions, the model is expected to have widespread applicability in
current molecular biological measurements.
2 Model
2.1 Multi-way, multi-view
We will generalize ANOVA to multi-view (multi-domain) analysis, restricting to two covariates and
two views for simplicity. Using ANOVA-style notation and assuming the views to be in the same
domain, the multivariate linear model for samples is
vd = αa + βb + (αβ)ab + γd + (αγ)ad + (βγ)bd + (αβγ)abd + noise, (1)
where a and b (a = 0, . . . A and b = 0, . . . B), are the two traditional independent covariates such
as disease and treatment, and d denotes the view.
For different values of d the domain of vd may vary, meaning different feature spaces with different
dimensionalities. We assume the samples of the different views to come in pairs, v = [x,y]. For the
rest of the paper we will change the notation for clarity to v1 = x, v2 = y, and assume a mapping
fx from the effects to the domain of x which is linear for now. Then,
x = fx(αa + βb + (αβ)ab) + f
x((α)xa + (β)
x
b + (αβ)
x
ab) + noise, (2)
assuming γd = 0, because it does not make sense to compare means of different domains, and that
the view-specific effects are in the same domain as the view-independent effects and hence need to
be transformed with the same function. The equation for y is analogous.
To our knowledge, there exists no method capable of studying the view-independent, and view-
dependent effects. In the next section we will introduce a model which will additionally assume that
the effects may be uncertain, resulting in a hierarchical Bayesian model.
2.2 Hierarchical model
We next formulate a hierarchical latent-variable model for the task of multi-way, multi-view learning
under “large p, small n” conditions. For this we need three components: (i) regularized dimension
reduction, (ii) combination of different data domains, and (iii) multi-way analysis. We formulate
each of these as part of a big generative model. We will first summarize the main components of the
model shown in Figure 1, and then describe each part in detail.
To deal with the small sample size n p problem, we reduce the dimensionality of the data x and
y from the two views into their respective latent variables xlat and ylat. This is done with factor an-
alyzers which assume that the variables come in groups, which is a strongly regularizing assumption
effective under the “large p, small n” conditions. The clustering assumption is particularly sensible
under the assumption that metabolomics data, our main application, contains strongly correlated
groups of variables [2].
The second necessary element is search for a view shared by the two different domains x and y,
needed for finding shared multi-way effects. Given paired data, this is a task for Bayesian CCA
(BCCA) [3, 4, 5] which introduces a new hiearchy level where a latent variable z captures the shared
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Figure 1: The hierarchical latent-variable model for multi-way, multi-view learning under “large p,
small n” conditions.
variation between the views. The view-specific variation has been implicitly modeled by view-
specific latent variables which have been integrated out, resulting in flexible covariance matrices
parameterized by the Ψ.
The third necessary element, the ANOVA-type two-way analysis is supplemented by assigning the
effect terms as priors on the latent variables z; in normal BCCA the prior is zero-mean. The observed
covariates a and b choose the correct effects for each sample. The covariates hence effectively
change the means of the data as in eqn (2), and the variation around the mean is modeled with
the rest of the model. The central differences from (2) are that the model is hierarchical, implying
that the arguments of the linear function fx have a distribution, and that the “noise” is structured,
stemming from all the latent variables. With these additions, the model will be better able to take
into account the uncertainty in the data.
The posterior is computed with Gibbs sampling. The Gibbs-formulas are included in the supple-
mentary material.
In effect the model, shown in Figure 1, consists of two factor analyzers, where the loadings assume
cluster memberships (multiplied with scales), a generative model of CCA, and population-specific
priors on z that assume ANOVA-type multi-way structure. We will now introduce the details of each
of these parts in turn.
2.2.1 Factor analysis model
We need to reduce dimensionality, which can be done by factor analysis (FA). The model [6] for n
exchangeable replicates is
xlatj ∼ N (0,Ψx)
xj ∼ N (µx +Vxxlatj ,Λx) . (3)
Here V x is the projection matrix that is assumed to generate the data vector xj from the latent
variable xlatj . The x
lat
j is a latent variable vector, whose elements are known as factor scores.
The Vxxlatj models such common variance of the data around the variable-means µ
x that can be
explained by factors common to all or many variables, effectively estimated from the sample covari-
ance matrix of the dataset. The sample covariance becomes decomposed into Σˆ = VxVxT + Λx,
where Λx is a diagonal residual variance matrix with diagonal elements σ2i , modelling the variable-
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specific noise not explained by the latent factors. The covariance matrix of xlat, Ψx, comes from
the CCA.
At this point, when n < p, Vx cannot be estimated due to the singularity of the sample covariance
matrix. To overcome the n  p problem, we now restrict Vx to a non-singular clustering matrix,
suitable for data containing highly correlated groups of variables.
2.2.2 Projection matrix that assumes grouped variables
We make the structured assumption that there are strongly correlated groups of variables in the data,
the generated values within the whole group being governed by one latent variable. The projection
matrix Vx is positive-valued, each row having one non-zero element corresponding to the cluster
assignment of the variable,
Vx =

λ1 0 0
0 0 λ2
...
...
...
0 λj 0
0 λj+1 0
...
...
...

. (4)
The location of the non-zero value on row i, vi, follows a multinomial distribution with one ob-
servation, with an uninformative prior distribution pii. The pii could also be used to encode prior
information on the known grouping of variables. The variation of each variable within a cluster
is assumed to be modeled by the same latent variable, but the scales λi may differ. The variable-
specific residual variances σ2i , that are the diagonal elements of Λ, follow a scaled Inv-χ
2 with an
uninformative prior.
In summary, we regularize the covariance matrix by assuming that the main correlations are positive
correlations between variables belonging to the same cluster. This correlation is mediated through
a common latent variable; this is a reasonable assumption for metabolomics data and, furthermore,
facilitates interpretation of the results.
2.2.3 Generative model of CCA
We need to combine different data domains, and for paired data that can be done with CCA. The
generative model of BCCA has been formulated [3, 7] for sample j as
zj ∼ N(0, I),
xlatj ∼ N(Wxzj ,Ψx), (5)
and likewise for y. Here we have assumed no mean parameter since the mean of the data is estimated
in the factor analysis part. The Wx is a projection matrix from the latent variables zj , and Ψx is a
matrix of marginal variances. The crucial thing is that the latent variables z are shared between the
two data sets, while everything else is independent. The prior distributions were chosen as
wl ∼ N(0, βlI),
βl ∼ IG(α0, β0),
Ψx,Ψy ∼ IW (S0, ν0). (6)
Here wl denotes the lth column of W, and IG and IW are shorthand notations for the inverse
Gamma and inverse Wishart distributions. The priors for the covariance matrices Ψx and Ψy are
conventional conjugate priors, and the prior for the projection matrices is the so-called Automatic
Relevance Determination (ARD) prior used for example in Bayesian principal component analysis
[8].
2.2.4 ANOVA-type model for latent variables.
We assume that the ANOVA-type effects act on the latent variables z, which allows access to effects
found in both the spaces xlat and ylat. They are modeled as population priors to the latent variables,
which in turn are given Gaussian priors αa, βb, (αβ)ab ∼ N (0, I).
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Figure 2: The graphical model describing the decomposition of covariate effects into shared and
view-specific ones. The figure expands the top part of Figure 1, leaving out the feature extraction
part and some parameters.
In the Kz-dimensional latent variable space we then have
zj = αa + βb + (αβ)ab + j , (7)
where j is a noise term. Note that the grand means are estimated in the lower level of hierarchy,
that is, directly in the x and y-spaces, and do not appear here.
To simplify the interpretation of the effects we center the grand means to the mean of one control
population. A similar choice has been done successfully in other ANOVA studies [9], and it does
not significantly sacrifice generality. We set the parameter vector µx, describing variable-specific
means, to the mean of the control group. One group now becomes the baseline to which other classes
are compared by adding main and interaction effects. For convenience, we will additionally change
the variables compared to the standard ANOVA convention, such that the terms α0, β0, αβ00,
(αβ)0b, and (αβ)a0 are not estimated. The differences between the populations are now modelled
directly with xlat and ylat, and hierarchically by the main effects αa, βb, (αβ)ab, a, b > 0.
In our case study, a and b have only two values and we have populations (a, b) =
(0, 0), (1, 0), (0, 1), (1, 1), and there are hence three terms α1, β1 and (αβ)11, that model the dif-
ference to the control population (a, b) = (0, 0).
In summary, the complete hierarchical model of Figure 1 is
α0 = 0,β0 = 0, (αβ)a0 = 0, (αβ)0b = 0
αa,βb, (αβ)ab ∼ N (0, I)
zj |j∈a,b ∼ N(αa + βb + (αβ)ab, I)
xlatj ∼ N(Wxzj ,Ψx)
xj ∼ N (µx +Vxlatj ,Λx). (8)
2.3 Decomposing covariate effects into shared and view-specific
So far we have not discussed how the model finds the view-related effects or, in our application,
tissue effects αxa, β
x
b , and (αβ)
x
ab, and likewise for y.
The Bayesian CCA assumes that the data is generated by a sum of view-specific latent variables
zx and zy , and shared latent variables z, and the former have been integrated out in the graphical
model of Figure 1. The way to implement the view-specific effects is to assign them as priors to the
view-specific latent variables. Then we do not want to integrate them out but include them explicitly
in the model as shown in Figure 2.
As a technical note, to make computation of the model faster and more reliable, we have further
included view-specific latent variables that do not have disease or treatment effects. They have been
integrated out, resulting in the covariance parameters Ψ in Figure 2. Their role is to explain away all
or most of the variation that is unrelated to the disease and treatment effects, so that Gibbs sampling
does not need to model all that variation. This trick should not change modeling results in the limit
of an infinite time for computation.
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In practice the decomposition in Figure 2 is implemented by restricting a column of Wx to be zero
for the y-specific components and vice versa for x.
2.4 Data preprocessing and model complexity selection
For simplicity and to reduce the number of parameters of the model, the data is preprocessed such
that for each variable the mean of the control population a = 0, b = 0 is subtracted and the variable
is scaled by the standard deviation of the control population. This fixes the scales λi to one and the
µx and µy to zero. The factor analysis part now models correlations of the variables. The possible
covariate effects are now comparable to the control population as discussed in Chapter 2.2.4
Model complexity, that is, the number of clusters and latent variables, is chosen separately for both
xlat and ylat by predictive likelihood in 10-fold cross-validation.
3 Results
We demonstrate the working of the method on generated data, and apply it to a disease study where
lipidomic profiles have been measured from several tissues of model mouse samples, under a two-
way experimental setup (disease and treatment), the two feature spaces (lipid profiles) are distinct
and samples paired.
3.1 Generated data
We generate data having known effects, and then study how well the model finds the effects as a
function of the number of measurements. There are three effects, in α, βy , and (αβ)x.
Each of the three effects have strength +2, the xlat and ylat are both 3-dimensional, and the x and
y are 200-dimensional. The σi = 1 for each variable i in x and y. The model is computed by Gibbs
sampling, discarding 1000 burn-in samples, and collecting 1000 samples for inference. To fix the
sign of the effects without affecting the results, each posterior distribution is mirrored, if necessary,
to have a positive mean, i.e. multiplied by the sign of the posterior mean.
The method finds the three generated effects, shown in Figure 3. The uncertainty decreases with
increasing number of observations. The shared effect is found with much less uncertainty since
there is evidence from both views. With low numbers of samples, there is considerable uncertainty
in the effects for view-specific components. In typical bioinformatics applications there may be
20-50 samples.
3.2 Lung cancer study
We then study data from a two-way, two-view, n  p, so far unpublished lung cancer mouse
model experiment. The diseased mice are compared to healthy control samples and, in addition,
some mice from both groups have been given a test anticancer drug treatment. There are thus
healthy untreated (9 mice/samples), diseased untreated (7), healthy treated (6) and diseased treated
(6) samples. Lipidomic profiles have been measured by Liquid Chromatography Mass Spectrometry.
The study has a two-way experimental setup, such that disease effect α, treatment effect β and an
interaction effect αβ on lipid groups are to be estimated. The high-dimensional lipidomic profiles
have been measured from several tissues of each mouse; the tissues have partly different lipids that
have not been matched, and even the roles of the matched lipids may be different in different tissues.
Hence, the tissues have different feature spaces with paired samples, implying a two-view study. We
will specifically study the relationship between blood and lung tissue, which is the most interesting
for diagnosis, since blood can be easily sampled.
3.2.1 Experiment 1. Effects shared by blood and disease tissue
Blood plasma (168 lipids) and lung tissue (68 lipids) were integrated with the method. The optimal
number of clusters for plasma was 6 and for lung 5, found by predictive likelihood. The method finds
a disease effect α and treatment effect β shared by both views (Fig. 4). The effect can be traced back
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Figure 3: The method finds the generated effects α = +2,βy = +2, and (αβ)x = +2. (effect
subscripts 1 and 11 have been dropped in the rest of the results section). The dots show posterior
mean and the thin lines include 95% of posterior mass, as a function of number of observations. A
consistently non-zero posterior distribution implies an effect found.
to the metabolite groups, by first identifying the responsible row of Wx and hence component of
xlat, and then the metabolite cluster from the Vx corresponding to the xlat component.
The results imply that a cluster of 12 lipids in lung and a cluster of 20 lipids in blood are mutually
coherently up-regulated due to disease, and additionally up-regulated by the treatment. Another
cluster of 13 lipids in lung was found down-regulated due to the disease and additionally down-
regulated due to treatment. The lipids of the down-regulated cluster are thus negatively correlated
with the up-regulated clusters. The results show that since no consistent interaction term (αβ) is
found, there is no indication that the treatment would cure the cancer effects. This confirms our
prior fear that the specific treatment might not be efficient. The treatment does, however, affect the
same groups of lipids as the disease, so investigating it as a potential cure was not a far-fetched
hypothesis.
The up-regulated cluster of blood plasma contains abundant triglycerides known to be coregulated,
the up-regulated cluster of lung contains lipotoxic ceramides [10] and proinflammatory lysophos-
phatidylcholines [11], while the down-regulated cluster of lung contains ether lipids, known as en-
dogenous antioxidants [12]. Our analysis reveals that the drug treatment enhances, not diminishes,
the proinflammatory lipid profile found in the disease.
3.2.2 Experiment 2. When connected to non-diseased tissue, only view-specific effects are
found
We then integrate plasma x with another tissue, heart (58 lipids) y. The results ( Figure 4), show that
the disease effect and the treatment effect are found only in the view-specific component of plasma.
This implies that there are no shared effects between plasma and heart, and in fact no consistent
effects are found for the heart tissue. The method finds, however, the same effects, α and β in the
plasma tissue as in Experiment 1 and for the same cluster of lipids, which is a sign that the method
works well.
4 Discussion
We have generalized ANOVA-type multi-way analysis to cases where multiple views of samples
having a multi-way experimental setup are available. The problem is solved by a hierarchical latent
variable model that extends the generative model of bayesian CCA to model multi-way covariate in-
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Experiment 1 Experiment 2
Figure 4: In experiment 1 (left), the method finds a disease effect α and a treatment effect β shared
between the two views, plasma (x) and lung (y) tissues. In experiment 2 (right), only view-specific
effects are found for plasma (x) when integrating with the heart tissue (y). No effects are found in
heart. The boxplots show quartiles and 95% intervals of posterior mass of the effects, a consistently
non-zero posterior distribution implies an effect found.
formation of samples by having population-specific priors on the shared latent variable of CCA. Fur-
thermore, the method is able to decompose the covariate effects to shared and view-specific effects,
treating the multiple views as one covariate. Finally, the method is designed for cases with high di-
mensionality and small sample-size, common in bioinformatics applications. The small sample-size
problem was solved by assuming that the variables come in correlated groups, which is reasonable
for the metabolomics application.
The modelling task is extremely difficult due to the complexity of the task and small sample-
size. Hence it was striking that the method was capable of finding covariate effects in a real-world
lipidomic multi-view, multi-way dataset.
In this work it was possible to estimate only three components, because the number of samples
was extremely low: a shared component and two view-specific components. If more than one
shared components are to be estimated, an unidentifiability problem occurs, since there is a rotational
ambiguity within the solution subspace. The problem can be solved by a deflation-type method,
where the components are computed one by one. Each posterior sample is now considered as a
converged starting point, and a second component is added and the model is sampled with having
the first component fixed. The last sample of each new sampled chain is collected for inference.
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